{"componentChunkName":"component---src-templates-posttemplate-js","path":"/post/COVID-19 vaccine","result":{"pageContext":{"data":{"node":{"title":"COVID-19 vaccine","timestamp":"2020-10-15T17:49+05:00","image":{"file":{"url":"//images.ctfassets.net/7vrkvphkfpmm/6MNMF7cKsoRRbSg0fkOGZA/03ed348d1320eece84556b409023bc40/image.png"}},"content":{"raw":"{\"data\":{},\"content\":[{\"data\":{},\"content\":[{\"data\":{},\"marks\":[],\"value\":\"As of October 2020, there were 321 \",\"nodeType\":\"text\"},{\"data\":{},\"marks\":[{\"type\":\"bold\"}],\"value\":\"candidates for vaccines\",\"nodeType\":\"text\"},{\"data\":{},\"marks\":[],\"value\":\" intended to provide acquired immunity against coronavirus disease 2019 (COVID‑19), a 2.5 fold increase since April.[1] In October, some 44 vaccine candidates were in clinical research: namely 34 in Phase I–II trials and 10 in Phase II–III trials.[1][2][3][4]\",\"nodeType\":\"text\"}],\"nodeType\":\"paragraph\"},{\"data\":{},\"content\":[{\"data\":{},\"marks\":[],\"value\":\"Previous work to develop a vaccine against the coronavirus diseases SARS and MERS\\n established knowledge about the structure and function of \\ncoronaviruses – which accelerated development during early 2020 of \\nvaried technology platforms for a COVID‑19 vaccine.[5]\",\"nodeType\":\"text\"}],\"nodeType\":\"paragraph\"},{\"data\":{},\"content\":[{\"data\":{},\"marks\":[],\"value\":\"The World Health Organization (WHO), the Coalition for Epidemic Preparedness Innovations (CEPI), and the Gates Foundation\\n (GF) are committing money and organizational resources for the prospect\\n that several vaccines will be needed to prevent continuing COVID‑19 \\ninfection.[6] The CEPI, which is organizing a US$2 billion worldwide fund for rapid investment and development of vaccine candidates,[7] indicated in September that clinical data to support licensure may be available by the end of 2020.[1] On 4 May 2020, the WHO organized a telethon which received US$8.1 billion in pledges from forty countries to support rapid development of vaccines to prevent COVID‑19 infections.[8]\\n At the same time, the WHO also announced the deployment of an \\ninternational \\\"Solidarity trial\\\" for simultaneous evaluation of several \\nvaccine candidates reaching Phase II–III clinical trials.[9]\",\"nodeType\":\"text\"}],\"nodeType\":\"paragraph\"}],\"nodeType\":\"document\"}"}}}}},"staticQueryHashes":[]}